Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Construction In Progress: ¥114 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600513 Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
61 GF Score
Price ¥14.88
GF Value ¥15.63
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Jiangsu Lianhuan Pharmaceutical Co Construction In Progress?

Jiangsu Lianhuan Pharmaceutical Co SHSE:600513 +1.02% 61 Construction In Progress is ¥114 Mil as of Jun. 2026. GuruFocus rates SHSE:600513 with a GF Score™ of 61/100 and a GF Value™ of ¥15.63 (Fairly Valued). The stock has 9 warning signs investors should review.

Jiangsu Lianhuan Pharmaceutical Co's quarterly construction in progress declined from Dec. 2025 (¥84 Mil) to Mar. 2026 (¥81 Mil) but then increased from Mar. 2026 (¥81 Mil) to Jun. 2026 (¥114 Mil).

Jiangsu Lianhuan Pharmaceutical Co's annual construction in progress declined from Dec. 2023 (¥226 Mil) to Dec. 2024 (¥100 Mil) and declined from Dec. 2024 (¥100 Mil) to Dec. 2025 (¥84 Mil).

Jiangsu Lianhuan Pharmaceutical Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Lianhuan Pharmaceutical Co Construction In Progress Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 184.84 68.31 225.81 100.22 84.34

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 116.60 43.50 84.34 81.14 113.85
SHSE:600513
61GF Score
Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Lianhuan Pharmaceutical Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥114 Mil mean?
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Construction In Progress of ¥114 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors.
Is Jiangsu Lianhuan Pharmaceutical Co's Construction In Progress too high?
Jiangsu Lianhuan Pharmaceutical Co's current Construction In Progress is ¥114 Mil. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Construction In Progress compare to ZTS?
Jiangsu Lianhuan Pharmaceutical Co's Construction In Progress of ¥114 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. Jiangsu Lianhuan Pharmaceutical Co's current Construction In Progress is ¥114 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.63, compared to a current price of ¥14.88 — trading 4.8% below its estimated fair value. The current Construction In Progress is ¥114 Mil. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Construction In Progress is ¥114 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥14.88 is trading 4.8% below its estimated GF Value™ of ¥15.63. GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600513:

  • Construction In Progress: ¥114 Mil
  • GF Value™: ¥15.63 vs. price of ¥14.88 (4.8% below fair value)
  • GF Score™: 61/100 with 9 warning signs

No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jiangsu Lianhuan Pharmaceutical Co Business Description

Address No. 9, Jiankang 1st Road, Yangzhou Bio-Health Industry Park, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225127
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
61GF Score

Get the complete analysis for SHSE:600513

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.88
Price
¥15.63
GF Value